[Cefotaxime in septicaemia and severe infections due to multiresistant Gram-negative bacilli (author's transl)].
Cefotaxime was given to 26 patients with serious infections resistant to other antibiotics. 15 patients were suffering from septicaemia due to Gram-negative bacilli, which were caused either by a single organism (13 cases:" of which Serratia in 6, Klebsiella in 3) or by several organisms (2 cases); 7 had upper urinary tract infections (caused by Serratia in 4 patients), and 6 had miscellaneous infections (two of these were purulent post-operative meningitis). The pathogens were usually resistant to ampicillin and cephalothin. Cefotaxime was administered at a daily dose of 3 g in 22 patients, irrespective of the renal function, and of 6 g in 4 patients (2 meningitis). Treatment included an aminoglycoside in 12 cases. The efficacy of cefotaxime was very satisfactory in 23 of the 26 patients.
D000328:Adult; D000368:Aged; D002439:Cefotaxime; D002511:Cephalosporins / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008581:Meningitis / Q000188:drug therapy; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy*; D012141:Respiratory Tract Infections / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy
D002511:Cephalosporins; D002439:Cefotaxime
Utilisation du céfotaxime dans les septicémies et états infectieux sévères à bacilles à Gram négatif multirésistants.